Tag: LIFE-BTK
Ramon Varcoe
Following his presentation last year of 12-month results from the “landmark” LIFE-BTK randomised controlled trial, Ramon Varcoe (Sydney, Australia) speaks to Vascular News about...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year...
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of...
New data and heated debates set to spark controversy in CX...
“These will be important, salutary lessons. Should a controversy arise again involving a proven efficacious therapy, we now know that stopping access to that...
Vascular News 101 – February 2024: North American Edition
In this issue:
LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Could metformin be first-ever medical treatment that is effective...
Vascular News 101 – February 2024: European Edition
In this issue:
LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Could metformin be first-ever medical treatment that is effective...
DRS combination of scaffold and antirestenotic drug will “really advance” treatment...
Principal investigators of the LIFE-BTK randomised controlled trial delve into the technological improvements underpinning the Esprit drug-eluting resorbable scaffold (DRS; Abbott) from its previous...
“First victory” in BTK space demonstrates lessons learned and paves the...
Lawrence Garcia (St Francis Hospital, New York, USA) speaks to Vascular News at VIVA 2023 (30 October–2 November, Las Vegas, USA) on lessons learned...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough...
Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023 (23–26 October, San Francisco, USA). The data show that, in...
Drug-eluting resorbable scaffolds “among most exciting technologies” in treatment of peripheral...
A temporary mechanical support with antiproliferative properties might combine two particular treatment qualities to fill a gap in the treatment armamentarium for peripheral arterial...
